Dr. Steven Grinspoon is a Professor of Medicine, Harvard Medical School, Chief of the MGH Metabolism Unit, and Director of the Nutrition Obesity Research Center at Harvard. He has had a long-standing interest in the metabolic and immune complications of HIV disease. He has served on the World Health Organization Technical Advisory Group on Nutrition in HIV Disease and Chaired the American Heart Association State of the Science Conference on Cardiovascular Disease in HIV-infected patients. His work has suggested significant cardiovascular disease in people with HIV (PWH) and highlighted the relative contributions of traditional risk factors, including diabetes and excess visceral fat accumulation, and of nontraditional risk factors, including inflammation and immune activation, using novel PET and CT techniques linking arterial inflammation to high risk vulnerable plaque. In this regard, he is a co-leader of the 7700 participant, global NIH-funded REPRIEVE study to prevent cardiovascular disease in HIV. In addition, he has shown efficacy of strategies to improve ectopic adipose tissue, leading the development and FDA approval of Tesamorelin, a growth hormone releasing analogue, for visceral fat reduction. More recently he has shown efficacy of this strategy to reduce excess hepatic fat, prevent fibrosis progression and improve inflammatory and oxidative gene pathways in PWH with NAFLD. For his work, Dr. Grinspoon was awarded the 2016 Aurbach Laureate award in translational research from the Endocrine Society. Dr. Grinspoon is a member of the American Society of Clinical Investigation and the Association of American Physicians, honoring his achievements. Important for this occasion, Steve is a member of the Board of Harvard Hillel, AJC New England and a trustee of the University of Rochester. He is a proud member of the Grinspoon family, funding PJ Library and the many programs of HGF.